GlassScriptPhysician profile
Zulfiqar Ali
NPI 1093740227
$10,074.49
in general payments reported to CMS, 2019-2025
40 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,714 · 2020: $570 · 2021: $1,245 · 2022: $1,017 · 2023: $1,318 · 2024: $1,859 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,528.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,573.89 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Novo Nordisk INC | $1,136.42 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $786.69 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $631.36 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $600.18 | 2019-2024 | Uzedy, Austedo Xr, Ajovy |
| Glaxosmithkline, LLC. | $575.33 | 2021-2025 | Arexvy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $449.38 | 2023-2025 | Lifevest |
| Pfizer INC. | $435.44 | 2019-2023 | |
| Amgen INC. | $413.45 | 2024-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $305.28 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $263.70 | 2021-2022 | |
| Gilead Sciences, INC. | $230.08 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.91 | 2024-2025 | |
| Amarin Pharma, INC. | $180.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $169.60 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zulfiqar Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.